INS and obesity disorder: Bezisterim inhibited inflammatory TNF activation and improved insulin sensitivity in rodent models (Wang et al., 2010; Lu et al., 2010), and in human participants with obesity-induced glucose intolerance or type-2 diabetes (Reading et al., 2013a,b).